Premium
P4‐338: Human Biodistribution and Radiation Dosimetry for the TAU Tracer 18 F‐THK‐5351
Author(s) -
Huang Kuo-Lun,
Chen Han-Shiuan,
Lin Kun-Ju,
Hsiao Ing-Tsung,
Wey Shiaw-Pyng,
Yen Tzu-Chen,
Okamura Nobuyuki
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.07.082
Subject(s) - nuclear medicine , dosimetry , biodistribution , medicine , absorbed dose , effective dose (radiation) , chemistry , biochemistry , in vitro
Clinic. Participants with typical AD and controls were enrolled in longitudinal studies of memory and aging at the Knight Alzheimer Disease Research Center. All individuals underwent amyloid (florbetapir F 18) and tau (F-AV-1451) PET imaging. Tau-PET data were converted to SUVRs relative to the cerebellum, aligned into a common anatomical space, and filtered with an 8mm Gaussian kernel. Average tau deposition was calculated for all three groups (Figure 1) and compared at a voxel-wise level controlling for age (Figure 2). Results:PPCD-AD and typical AD participants were matched for dementia severity. PPCD-AD patients were younger than participants with typical AD (median years, PPCDAD1⁄461 [55-65], AD1⁄476 [65-90], p1⁄40.002). Memory impairment was common to both populations; however, visuospatial complaints, alexia and apraxia were unique to patients with PPCDAD—distinguishing the clinical subtype. Individuals with PPCDAD and typical AD demonstrated elevated tau deposition throughout the medial temporal lobes and precuneus, relative to controls.The PPCD-AD group had statistically higher F-AV1451 uptake in primary and secondary visual areas, as well as bilateral motor cortices, when compared to participants with typical AD. Conclusions: Tau deposition within the temporal lobes was common in all individuals with very mild dementia due to AD. Significantly greater deposition was observed in the occipital lobes of patients with PPCD-AD, suggesting that the occipital regions are uniquely vulnerable to tau deposition early in the course of PPCDAD. Acknowledgements: F-AV-1451 precursor and technology was supported by Avid Radiopharmaceuticals.